| 1/4 | US=69 / Câncer Stewart DJ. Targeted therapy in non-small cell lung cancer. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 125-56. ISBN 978-1-60327-423-4. TERAPIA-ALVO; NAO-PEQUENAS DE CANCER DE PULMAO DE CELULAS; EGFR; ERLOTINIB; GEFITINIB; VEGFR |
| 2/4 | US=90 / Biol/Mol Thomson S, Haley JD, Yauch R. EGFR in tumorigenesis and EGFR tyrosine kinase inhibitors in cancer therapy: cellular sensitivity to EGF receptor inhibitors. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 353-68. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1. EGFR; HER2; HER3; ERLOTINIB; A TRANSICAO EPITELIAL MESENQUIMAL; INIBIDORES DE QUINASE DE TIROSINA |
| 3/4 | US=90 / Biol/Mol Buck E, Eyzaguirre A, Iwata KK. EGFR in tumorigenesis and EGFR tyrosine kinase inhibitors in cancer therapy: utilizing combination of molecular targeted agents to sensitize tumor cells to EGFR inhibitors. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 369-82. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1. EMT; TRANSICAO EPITELIAL MESENQUIMAL; ERLOTINIB; EGFR; IGF-1R; ER; HER3; MTOR; HDAC; SRC; COX-2 |
| 4/4 | US=92 / Biol/Mol Deininger M. Established cancer therapies: tyrosine kinase inhibitors. In: Gewirtz DA, Holt SE, Grant S. Apoptosis, senescence and cancer. 2 ed. New Jersey: Humana Press, 2007. p. 477-508. (Cancer Drug Discovery and Development) ISBN 978-1-58829-527-9. TERAPIA-ALVO; BCR-ABL; FLT3; EGFR; TYROSISE INIBITORS QUINASE; IMATINIB; GEFITINIB; ERLOTINIB; CANCER; LEUCEMIA |